The kinetics of Torque Teno virus plasma load following calcineurin inhibitor dose change in kidney transplant recipients.

Torque Teno virus calcineurin inhibitor immunologic monitoring kidney transplantation

Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
Mar 2024
Historique:
revised: 02 02 2024
received: 21 11 2023
accepted: 10 03 2024
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 21 3 2024
Statut: ppublish

Résumé

Torque Teno virus (TTV) is nonpathogenic, highly prevalent, and reflects the immune status of its host. Thus, TTV plasma load was suggested for the guidance of immunosuppression post solid organ transplantation. The present study was designed to determine the kinetics of TTV following changes in calcineurin inhibitor (CNI) dose. A total of 48 adult recipients of a kidney graft transplanted at the Medical University of Vienna between 2018 and 2019 with isolated changes in CNI dose were selected from the prospective TTV-POET trial. TTV plasma load was quantified by in-house PCR. At Day 30 following CNI dose adaptation (median 33% of daily dose) no changes in TTV load were noted. However, at Day 60, following CNI dose reduction a lower TTV load of 6.4 log

Identifiants

pubmed: 38511586
doi: 10.1002/jmv.29554
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e29554

Subventions

Organisme : Horizon 2020 Framework Program

Informations de copyright

© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Références

Focosi D, Antonelli G, Pistello M, Maggi F. Torquetenovirus: the human virome from bench to bedside. Clin Microbiol Infect. 2016;22(7):589‐593.
Doberer K, Haupenthal F, Nackenhorst M, et al. Torque teno virus load is associated with subclinical alloreactivity in kidney transplant recipients: a prospective observational trial. Transplantation. 2021;105(9):2112‐2118.
Schiemann M, Puchhammer‐Stöckl E, Eskandary F, et al. Torque Teno virus load—inverse association with antibody‐mediated rejection after kidney transplantation. Transplantation. 2017;101(2):360‐367.
Strassl R, Doberer K, Rasoul‐Rockenschaub S, et al. Torque teno virus for risk stratification of acute biopsy‐proven alloreactivity in kidney transplant recipients. J Infect Dis. 2019;219(12):1934‐1939.
Strassl R, Schiemann M, Doberer K, et al. Quantification of torque teno virus viremia as a prospective biomarker for infectious disease in kidney allograft recipients. J Infect Dis. 2018;218(8):1191‐1199.
Gottlieb J, Reuss A, Mayer K, et al. Viral load‐guided immunosuppression after lung transplantation (VIGILung)‐study protocol for a randomized controlled trial. Trials. 2021;22(1):48.
Haupenthal F, Rahn J, Maggi F, et al. A multicentre, patient‐ and assessor‐blinded, non‐inferiority, randomised and controlled phase II trial to compare standard and torque teno virus‐guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT. Trials. 2023;24(1):213.
Thaunat O. TAOIST study. (Personal communication, 20th October, 2023).
Doberer K, Schiemann M, Strassl R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—a prospective observational trial. Am J Transplant. 2020;20(8):2081‐2090.
Gorzer I, Haupenthal F, Maggi F, et al Validation of plasma Torque Teno viral load applying a CE‐certified PCR for risk stratification of rejection and infection post kidney transplantation. J Clin Virol. 2023;158:105348.
Jaksch P, Görzer I, Puchhammer‐Stöckl E, Bond G. Integrated immunologic monitoring in solid organ transplantation: the road toward torque Teno virus‐guided immunosuppression. Transplantation. 2022;106(10):1940‐1951.
Maggi F, Pifferi M, Fornai C, et al. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol. 2003;77(4):2418‐2425.
Regele F, Heinzel A, Hu K, et al. Stopping of mycophenolic acid in kidney transplant recipients for 2 weeks peri‐vaccination does not increase response to SARS‐CoV‐2 vaccination—a non‐randomized, controlled pilot study. Front Med. 2022;9:914424.
Benning L, Reineke M, Bundschuh C, et al. Quantification of Torque Teno Virus load to monitor short‐term changes in immunosuppressive therapy in kidney transplant recipients. Transplantation. 2023;107:e363‐e369.
Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long‐term outcomes. Nephrol Dial Transplant. 2019;34(7):1240‐1250.
Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre‐emptive intervention in pediatric kidney recipients. Am J Transplant. 2007;7(12):2727‐2735.
Spezia PG, Focosi D, Baj A, et al. TTV and other anelloviruses: the astonishingly wide spread of a viral infection. Asp Mol Med. 2023;1:100006.

Auteurs

Florina Regele (F)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Frederik Haupenthal (F)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Konstantin Doberer (K)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Irene Görzer (I)

Center for Virology, Medical University of Vienna, Vienna, Austria.

Sebastian Kapps (S)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Robert Strassl (R)

Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria.

Gregor Bond (G)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Classifications MeSH